Abstract
INTRODUCTION. Incidence of Guillain Barre syndrome is 1.2 to 1.7 for 100.000 habs in Colombia. Besides mortality this entity has a high socio economical impact because of its important probability to generate disability. We show the data correspondent to the group of patients with diagnosis of guillain barre syndrome in a 4th level colombian hospital emphasizing in clinical and pronostic factors.
OBJECTIVE. To describe clinical and demographic features and outcome of patients with Guillain Barré Syndrome in the Hospital San Vicente de Paul in Medellin (Colombia) between 2001-2005.
MATERIALS AND METHODS. Observational, descriptive study. Between january 2001 and 2005.
RESULTS. There were 46 patients; 54.3% were women age mean 39.4 years (+ 17.6). The ascendent and demyelinating clinical forms were the commonest. The axonal forms had the longest stay in the Hospital. 50% of the patients receiving immunotherapy, 47.8% plasmapheresis and 52.2% receiving immunotherapy, 47.8% plasmapheresis and 52.2% receiving immunoglobulin. 50% of the patients of the plasmapheresis score in the Hughes scale was in the immunoglobulin groups. Pneumonia was the main complication. In comparison with the literature, we found similar frecuency of the syndrome in both genders. Three patients died. The follow up for one year in 67.4% of patients showed sequels in 23.3% of them.
CONCLUSION. It is necessary more information to general practitioners, in order to avoid late attention of patients with guillain barre syndrome.
References
fisher C. An unusual variant of acute idiopathic poly- neuritis: Syndrome of ophthalmoplegia, ataxia and arreflexia. N Engl J Med 1956; 57: 255.
Wigbert W, Mulder D, Lambert E. The Landry-Guillain- Barré-Strohl Syndrome or Polyradiculoneurpathy: Historical Review, Report on 97 Patients, and Present Concepts. Mayo Clin Proc 1964; 39: 427-451.
Thomas P, Dyck P. Peripheral Neuropathy, Disease of the peripheral nervous system. Philadelphia: Saunders Company, 1993: 1437-1497.
Asbury A, Cornblath D. Assesment of current diag- nostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27: s21-24.
Jacobs B, Van Doorn P, Schmitz P, et al. Campylobacter jejuni Infections and Anti GM1 Antibodies in Guillain Barré Syndrome. Ann Neurol 1996; 40: 181-187.
Rees J, Gregson N, Hughes R. Anti Ganglioside GM 1 Antibodies in Guillain Barré Syndrome and Their Relation- ship to Campylobacter jejuni Infection. Ann Neurol 1995; 38: 809-816.
Palacios E. Síndrome de Guillain Barre estudios clínico y paraclínico de 339 pacientes. Acta Med Colomb 1982; 712: 69-79.
fernández E. El Síndrome de Guillain Barre en Colom- bia: Estudio hospitalario y seguimiento extrahospitalario de 38 pacientes. Acta Neurol Colomb 1988; 4: 145-150.
Lazzarino, N. Opsoclonus in a patient with Guillain- Barré syndrome. Act Neurol Scan 1992; 85: 363-364.
Brody I, Wilkins R, Durham N. Guillain-Barré-Strohl Syndrome. Arch Neurol 1968; 18: 449-451.
Van Der Meche f, Schmitz P. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-29.
Pritchard, J. What’s new in Guillain-Barré syndrome? Practical Neurol 2006; 6: 208- 217.
Gordon P, Wilbourn A. Early Electrodiagnostic findings
in Guillain Barré syndrome. Arch Neurol 2001; 58: 913-917.
Vedeler C. Inflammatory neuropathies: update. Curr Opin Neurol 2000; 13: 305-309.
Lawn N. Anticipating mechanical ventilation in Guillain-Barré Syndrome Arch Neurol 2001; 58: 893-898.
Kleywerg R, Van Der Meche f. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psych 1991; 54: 957-60.
fletcher D, Lawn N, fracp W, Troy D, Wijdicks E. Long-term outcome in patients with Guillain–Barré syn- drome requiring mechanical ventilation. Neurol 2000; 54: 2311-2315.
Chalela J. Pearls and Pitfalls in the Intensive Care Management of Guillain-Barré Syndrome. Semin Neurol 2001; 21: 399-405.
Henderson R, Lawn f, fletcher f, McClelland R, Wid- dicks E. The morbidity of Guillain-Barré syndrome admitted to the intensive care unit . Neurol 2003; 60:17–21.
The Guillain-Barré study group: Plasmapheresis and acute Guillain-Barré syndrome. Neurol 1985; 35: 1096-1104.
French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-761.
French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992; 32: 94-97.
Raphael J, Chevret S, Hughes R, Annane D. Plasma exchange for Guillain-Barré syndrome (Cochrane Review). The Cochrane Library 2004.
Plasma Exchange/Sandoglobulin Guillain-Barré Syn- drome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.
Hughes R, Wijdicks E, Barohn R, et al. Practice param- eter: Immunotherapy for Guillain–Barré syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 2003; 61: 736–740.
Hahn A. The Challenge of Respiratory dysfunction in Guillain-Barré Syndrome. Arch Neurol 2001; 58: 871-872.
Griffin J, Stoll G, Li C, Tyor W, Cornblath D. Mac- rophage responses in inflammatory demyelinating neuropa- thies. Ann Neurol 1990; 27: S64-68.
fernández J, Rojas J, Núñez M, Miralles E, Bravo M. Síndrome de Guillain-Barré en Unidad de Cuidados Inten- sivos. Rev Neurol 2001; 33: 318-324.
Hahn A. Intravenous immunoglobulin treatment in peripheral nerve disorders-indications, mechanisms of action and side-effects. Curr Opin Neurol 2000; 13: 575-582.
Hughes R, Raphael J, Swan A, Van Doorn P. Intra- venous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). The Cochrane Library, 2004.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.